Coeptis Therapeutics — Investor Presentation (November 2022)
27 slides from Coeptis Therapeutics's investor presentation, Nov 3, 2022

Slide 1: Coeptis Therapeutics Holdings, Inc. Corporate Overview
1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP

Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 © 2022 Coeptis Therapeutics, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Coeptis made in connection with this Presentation, constitute “forward - loo

Slide 3: Important Legal Disclaimers
3 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers No Offer or Solicitation: This Presentation is for informational purposes and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Coeptis, or any o

Slide 4: Important Legal Disclaimers cont'd.
4 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers cont’d. This Presentation is not a substitute for any other document that Coeptis may file with the SEC, and this Presentation is qua lif ied in its entirety by such SEC filings. Readers may obtain free copies of all

Slide 5: Coeptis Therapeutics
5 © 2022 Coeptis Therapeutics, Inc. All rights reserved COEPTIS THERAPEUTICS We are a Pittsburgh, PA based pharmaceutical company founded by an experienced team developing innovative cell therapy platforms in oncology .

Slide 6: Corporate Highlights
6 © 2022 Coeptis Therapeutics, Inc. All rights reserved NASDAQ - LISTED CELL THERAPY COMPANY Coeptis Therapeutics Holdings, Inc. (COEP) is now a Nasdaq - listed cell therapy company following the completed Business Combination of Coeptis Therapeutics, Inc. with Bull Horn Holdings Corp. OPTION FOR CA

Slide 7: Business Combination Completion
7 © 2022 Coeptis Therapeutics, Inc. All rights reserved Completed Business Combination whereby Coeptis Therapeutics, Inc. has become a wholly - owned subsidiary of Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), formerly Bull Horn Holdings, Corp. GO - FORWARD PLAN Business Combination expected t

Slide 8: Driving Growth, Building Value
8 © 2022 Coeptis Therapeutics, Inc. All rights reserved Driving Growth, Building Value Q2 ‘21 5/18/21 Coeptis Enters into Exclusive Option Agreements w/ VyGen - Bio 8/19/21 Coeptis Therapeutics Partners with VyGen - Bio, Inc. to Co - develop Two Assets Designed to Improve the Treatment of CD38 - Rel

Slide 9: SNAP-CAR: A Multi-Antigen CAR T Platform
9 © 2022 Coeptis Therapeutics, Inc. All rights reserved SNAP - CAR A MULTI - ANTIGEN CAR T PLATFORM

Slide 10: Coeptis Option – University of Pittsburgh
10 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into an option agreement with the University of Pittsburgh for the exclusive rights to license multiple CAR T technologies that offer the potential to address a range of hematologic and solid tumors. Option agreement involves t

Slide 11: Immunotherapy Challenges
11 © 2022 Coeptis Therapeutics, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Reducing potential toxicity: The therapeutic activity of the SNAP - CAR T cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over - activity. We

Slide 12: CAR T Platform – Market Opportunities
12 © 2022 Coeptis Therapeutics, Inc. All rights reserved CAR T Platform – Market Opportunities CAR T offers the potential to revolutionize cancer treatment; however, there are opportunities to improve upon current CAR T therapies that could enable the technology to be utilized with additional types

Slide 13: SNAP-CAR – Potential Advantages
13 © 2022 Coeptis Therapeutics, Inc. All rights reserved SNAP - CAR T cells can be controlled by the antibody dose, which may allow clinicians to potentially reduce toxicity from over - activity. Potential to minimize cancer relapse by combining SNAP - CAR T cells with antibodies targeting multiple

Slide 14: GEAR-NK & GEAR Diagnostic Targeting CD38 Cancers
14 © 2022 Coeptis Therapeutics, Inc. All rights reserved GEAR - NK & GEAR DIAGNOSTIC TARGETING CD38 CANCERS

Slide 15: VyGen-Bio option agreements for CD38 technologies
15 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis entered into two exclusive option agreements with VyGen - Bio, Inc., a majority - owned subsidiary of Vycellix, Inc., involving technologies designed to improve the treatment of CD38 - related cancers. Coeptis will assist VyGen - Bio i

Slide 16: GEAR-NK (CD38) Strategy
16 © 2022 Coeptis Therapeutics, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti

Slide 17: Current Anti-CD38 Pathway vs Pathway with GEAR-NK
17 © 2022 Coeptis Therapeutics, Inc. All rights reserved Animations herein are provided as visual aids to help articulate hypothesized proof - of - concept in a general manner and do not de pict precise scientific mechanisms - of - action. Anti - CD38 mAbs (Infused antibodies from current cancer tre

Slide 18: CD38-GEAR-NK – Market Opportunity
18 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - GEAR - NK – Market Opportunity CD38 - GEAR - NK could change how CD38 - related cancers are treated by protecting CD38+ NK cells from destruction by anti - CD38 mAbs. Opportunity to improve the treatment of CD38 - related cancers, inclu

Slide 19: CD38-Diagnostic – Product Overview
19 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - Diagnostic is an in vitro screening tool to be used prior to initiation of mAb therapy. Being developed to pre - determine which cancer patients are most likely to benefit from targeted anti - CD38 mAb therapies , either as monotherapy

Slide 20: CD38-Diagnostic – Market Opportunity
20 © 2022 Coeptis Therapeutics, Inc. All rights reserved CD38 - Diagnostic – Market Opportunity Could prevent patients from being subjected to ineffective therapy and enable significant savings to healthcare systems CD38 - Diagnostic provides opportunity to make more cost - effective medical decisio

Slide 21: CD38-Diagnostic – Value Proposition
21 © 2022 Coeptis Therapeutics, Inc. All rights reserved FLEXIBILITY SPEED TO MARKET RETURN ON INVESTMENT Designed to be used as a companion with CD38 GEAR - NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors Opportunity to expand the

Slide 22: GEAR Platform Advantages
22 © 2022 Coeptis Therapeutics, Inc. All rights reserved Each GEAR platform being designed to be deployed independently or collectively to further bolster the likelihood of a durable therapeutic response . GEAR Diagnostic being designed to determine the most appropriate anti - CD38 mAb . GEAR NK bei

Slide 23: Coeptis Scientific Advisory Board
23 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Scientific Advisory Board Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Evren Alici M.D., Ph.D. Arnika K. Wagner, Ph.D. Assista

Slide 24: Coeptis Management Team
24 © 2022 Coeptis Therapeutics, Inc. All rights reserved COEPTIS MANAGEMENT TEAM Dave Mehalick Co - Founder, President & CEO 30 years of diverse business experience in healthcare, information technology and finance including consulting, capital markets, private equity, and investments Christine Shee

Slide 25: Anticipated Development Plans
25 © 2022 Coeptis Therapeutics, Inc. All rights reserved Anticipated Development Plans • Execute Sponsored Research Agreement with the University of Pittsburgh to expand pre - clinical work • Upon completion of GAP analysis, initiate IND development plans with leading CRO SNAP - CAR • Pre - clinical

Slide 26: Coeptis Investment Thesis
26 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Investment Thesis Cell and gene therapies have the potential to “disrupt” current treatment paradigms. Early - stage development assets in this space are being routinely acquired by larger pharma companies. CAR T technologies being dev

Slide 27: Coeptis Investor Relations Contact
27 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Investor Relations Contact: Bill Borden Senior Vice President Tiberend Strategic Advisors Mobile: 732 - 910 - 1620 [email protected] coeptistx.com
Source: SEC EDGAR · 8-K filed Nov 3, 2022
More decks from Coeptis Therapeutics Inc
Investor Presentation (December 2023)20 slides · Dec 5, 2023
Investor Presentation (June 2023)29 slides · Jun 6, 2023
SPAC Merger (September 2022)30 slides · Sep 21, 2022
SPAC Merger (September 2022)29 slides · Sep 7, 2022
SPAC Merger (July 2022)31 slides · Jul 6, 2022
Bull Horn Holdings — SPAC Merger (July 2022)31 slides · Jul 6, 2022